HAVCR2 and neoplasm: Overall, the data paint a picture of an immune-active yet checkpoint-inhibited TME, where both tumor cells and immune cells contribute to immunosuppression through PD-L1 expression and T cell PD-1/TIM-3 (co-)expression.